<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476317</url>
  </required_header>
  <id_info>
    <org_study_id>17-014343</org_study_id>
    <secondary_id>5K23DK109136-02</secondary_id>
    <nct_id>NCT03476317</nct_id>
  </id_info>
  <brief_title>Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</brief_title>
  <acronym>Holiday</acronym>
  <official_title>An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a novel gut microbiota-targeted&#xD;
      therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the&#xD;
      management of active Crohn's Disease (CD) or indeterminate colitis (IBDU) that is refractory&#xD;
      to conventional, immunosuppressive therapy. In addition, the study will determine the effect&#xD;
      of PEG lavage alone on fecal calprotectin and gut microbiota in patients who are undergoing a&#xD;
      PEG lavage for clinical care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will evaluate the efficacy of a novel treatment regimen, employing&#xD;
      non-immunosuppressive medications, in the management of refractory CD or IBDU. Refractory&#xD;
      patients include those patients who have experienced loss of responsiveness (LOR) or primary&#xD;
      nonresponse to an immunomodulator or a biologic. Investigators will treat participants with a&#xD;
      combination of gut microbiota-targeted therapies to restore a healthy gut microbiome&#xD;
      composition. Investigators believe that this strategy will both treat the gut inflammation&#xD;
      associated with inflammatory bowel disease (IBD) as well as salvage response to immune&#xD;
      suppressive therapies.&#xD;
&#xD;
      Investigators will also evaluate the effect of PEG lavage alone on fecal calprotectin and gut&#xD;
      microbiota. Participants in this arm, will be undergoing a PEG lavage in preparation for a&#xD;
      endoscopy for clinical care. They will be asked to provide stool samples, prior to and after&#xD;
      their PEG lavage. Participants will not be receiving any investigational treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity by Pediatric Crohn's Disease Activity Index</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>The primary endpoint will be the change in disease activity, as measured by Pediatric Crohn's Disease Activity Index (PCDAI) score, between the enrollment visit and Day 15. All participants who withdraw for any reason prior to day 15 will be considered treatment failures. The Pediatric Crohn's Disease Activity Index is a clinical score which takes into account general well being, degree of abdominal pain, number of liquid stools per day, abdominal physical examination, and Crohn's disease complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in disease activity by fecal calprotectin (FCP)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>The second primary outcome measure will be the change in disease activity, as measured by fecal calprotectin, between the enrollment visit and day 15. The fecal calprotectin is a stool test which measures intestinal inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (CRP)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>A secondary outcome measure will be the change in C-reactive protein between the enrollment visit and day 15. The C-reactive protein is a blood test which measures systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the treatment regimen based on medication side effects and/or adverse events</measure>
    <time_frame>105 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FCP in Group 2 participants</measure>
    <time_frame>Baseline, Day 5 after procedure, and Day 12 after procedure in Group 2 participants</time_frame>
    <description>A secondary outcome measure will be the change in fecal calprotectin between stool samples collected at baseline, Day 5 after procedure and Day 12 after procedure in Group 2 participants.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Group 1-Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Oral suspension 4 times daily (Day 1-14)</description>
    <arm_group_label>Group 1-Fluconazole</arm_group_label>
    <arm_group_label>Group 1-Placebo</arm_group_label>
    <other_name>Vancocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neomycin</intervention_name>
    <description>Oral three times daily (Days 1-3)</description>
    <arm_group_label>Group 1-Fluconazole</arm_group_label>
    <arm_group_label>Group 1-Placebo</arm_group_label>
    <other_name>Neo-Fradin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Oral twice daily (Days 4-14)</description>
    <arm_group_label>Group 1-Fluconazole</arm_group_label>
    <arm_group_label>Group 1-Placebo</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol 3350</intervention_name>
    <description>Dissolved in Gatorade on day 2</description>
    <arm_group_label>Group 1-Fluconazole</arm_group_label>
    <arm_group_label>Group 1-Placebo</arm_group_label>
    <other_name>Miralax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Orally once daily (Day 1-14)</description>
    <arm_group_label>Group 1-Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females 6-18 years of age&#xD;
&#xD;
          -  Current weight &gt;10 kg (or 22 lb)&#xD;
&#xD;
          -  Ability to swallow pills&#xD;
&#xD;
          -  Normal kidney function&#xD;
&#xD;
          -  Normal Aspartate transaminase (AST), Alanine transaminase (ALT), and alkaline&#xD;
             phosphatase&#xD;
&#xD;
          -  Active CD or IBDU defined as PCDAI ≥ 30&#xD;
&#xD;
          -  C-Reactive Protein (CRP) ≥ 15mg/L (or 1.5mg/dL) or fecal calprotectin (FCP)&gt;350mcg/g&#xD;
             (within one month of enrollment)&#xD;
&#xD;
          -  Have been treated with one of the following therapies for at least 8 weeks with&#xD;
             primary nonresponse or an initial response, followed by loss of response [LOR]&#xD;
             (self-reported worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine,&#xD;
             methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab,&#xD;
             vedolizumab, or ustekinumab **These medications must have been administered at&#xD;
             standard, therapeutic dosages.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or intolerance to aminoglycosides or any of the medications used in this&#xD;
             study&#xD;
&#xD;
          -  Current use of one or more of the following medications: 5-fluorouracil, digoxin,&#xD;
             anticoagulants, theophylline, phenytoin, probenecid, duloxetine, clozapine,&#xD;
             sildenafil, hydrochlorothiazide, cyclosporine, hypoglycemics, terfenadine, tacrolimus,&#xD;
             rifabutin, midazolam, and voriconazole&#xD;
&#xD;
          -  Known diagnosis of diabetes mellitus&#xD;
&#xD;
          -  Known or suspected structuring disease producing obstructive symptoms&#xD;
&#xD;
          -  Active Clostridium difficile infection&#xD;
&#xD;
          -  Prolonged QTc interval as seen on enrollment EKG&#xD;
&#xD;
          -  Current use of antibiotics&#xD;
&#xD;
          -  Starting or increasing the dose of an IBD related medication within 4 weeks of&#xD;
             screening&#xD;
&#xD;
        Group 2&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Males or females 10 years of age and older.&#xD;
&#xD;
          -  Patients undergoing a clinical GI endoscopy due to suspicion for active intestinal&#xD;
             inflammation determined by physician global assessment (PGA).&#xD;
&#xD;
          -  Undergoing a bowel preparation as part of clinical care.&#xD;
&#xD;
          -  Parental/guardian permission (informed consent) and if appropriate, child assent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Antibiotic use within the past 30 days.&#xD;
&#xD;
          -  Current presence of an ostomy bag.&#xD;
&#xD;
          -  Patients undergoing a non- polyethylene glycol 3350 cleanout.&#xD;
&#xD;
          -  Unwillingness to provide informed consent.&#xD;
&#xD;
          -  Parents/guardians or subjects who, in the opinion of the Investigator, may be&#xD;
             non-compliant with study schedules or procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Albenberg, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2018</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Neomycin</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03476317/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

